Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Drug Discovery and Development India

Subrahmanyam Vangala's Biography

Subrahmanyam Vangala, Founder and Chief Executive Officer, ReaGene Biosciences Private Limited

Dr. Subrahmanyam Vangala is currently Founder and Chief Executive Officer at ReaGene Biosciences Private Limited (Bangalore, India). He is an experienced pharma scientist and executive with more than two decades of leadership experience with increasing responsibilities, at global pharma in USA (Wyeth, JNJ, Purdue Pharma and Shire) and Contract Research Organizations in India (Sai Life and Advinus). He received his PhD Degree in Biochemical Mechanisms of Chemical Carcinogenesis from the Department of Biochemistry, Memorial University of Newfoundland, Canada. He conducted his postdoctoral research in Molecular Toxicology department at University of Colorado at Boulder, and continued as a Specialist Scientist (Research Assistant Professor) in Molecular Toxicology at School of Public Health, University of California, Berkeley.
His industrial experience was focused on, but not limited to, new drug discovery and development with expertise in DMPK, Bioanalytical, Clinical Pharmacology and Toxicology. Supported more than 30 IND and 10 NDA submissions including ANDAs. Dr. Subrahmanyam to his credit worked in preclinical development programs for marketed new drugs including Zaleplon, Tygacil and Canagliflozin. He has interacted in project teams representing Toxicology, DMPK, Bioanlaytical and Clinical Pharmacology research and reviewed data packages of new drug candidates nominated for preclinical development and clinical development. Other areas he gained knowledge include drug-drug interactions, pre-formulation development, drug repurposing, specialty pharmaceuticals, generics, biologics/biosimilars, medical devices, pharmacogenomics, and metabolomics. He participated in several due-diligence activities involving in-licensing activities.
He brings with him, unique insights into translational research. He is on the scientific advisory board of Bioagile therapeutics and on the editorial board of journals related to toxicology and analytical research. He has 50 plus peer reviewed publications in peer reviewed journals including invited book chapters. He has chaired several international symposia in predictive toxicology, idiosyncratic drug toxicity and DMPK.

Subrahmanyam Vangala Image

ADMET Technologies in Drug Design and Discovery: Helping the Medicinal Chemist in Optimal Drug Design

Friday, 11 September 2015 at 10:40

Add to Calendar ▼2015-09-11 10:40:002015-09-11 11:40:00Europe/LondonADMET Technologies in Drug Design and Discovery: Helping the Medicinal Chemist in Optimal Drug DesignDrug Discovery and Development India in

This talk will focus on how ADMET technologies have evolved in the past twenty years while becoming very critical for Medicinal Chemists to design novel NCEs.

Add to Calendar ▼2015-09-09 00:00:002015-09-11 00:00:00Europe/LondonDrug Discovery and Development IndiaDrug Discovery and Development India in